The emerging role of immunotoxins in leukemia and lymphoma

被引:20
作者
Winkler, U [1 ]
Barth, S [1 ]
Schnell, R [1 ]
Diehl, V [1 ]
Engert, A [1 ]
机构
[1] UNIV COLOGNE, INNERE MED KLIN 1, D-50924 COLOGNE, GERMANY
关键词
cancer therapy; immunotoxins; minimal residual disease; monoclonal antibodies; review;
D O I
10.1023/A:1008247110494
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite important advances in conventional cancer therapy, there is still a strong need for new approaches in order to reduce cancer death rates, which have not been drastically influenced in the past ten years. Since minimal residual disease is regarded as the major cause for relapses of malignant diseases, immunotherapeutic strategies utilizing monoclonal antibodies (MoAbs) or their conjugates to target 'dormant' tumor cells have increasingly attracted scientific interest. Immunotoxins (ITs) constructed by chemically linking plant or bacterial toxins to a MoAb can selectively kill their target cells when internalized after binding to specific cell surface receptors. Many different ITs against various blood-borne as well as solid malignancies have been successfully tested in vitro and in animal models. Chemically linked ITs and recombinant fusion toxins generated by using DNA technologies are currently being evaluated for their anti-tumor activity in several clinical phase I/II/III trials. While serious side effects are rare, there are still many problems to be solved, such as the immunogenicity of the toxin and/or antibody moiety or the poor capacity of ITs to penetrate large solid tumors. At the moment only heavily pretreated patients with massive tumor burden are admitted to early clinical studies, so that even minor responses after IT treatment are encouraging. However, minimal residual disease is expected to be most amenable to IT therapy.
引用
收藏
页码:139 / 146
页数:8
相关论文
共 47 条
[1]  
AMLOT PL, 1993, BLOOD, V82, P2624
[2]   SELECTION OF HUMAN ANTIHAPTEN ANTIBODIES FROM SEMISYNTHETIC LIBRARIES [J].
BARBAS, CF ;
AMBERG, W ;
SIMONCSITS, A ;
JONES, TM ;
LERNER, RA .
GENE, 1993, 137 (01) :57-62
[3]  
BLAZAR BR, 1987, PROGR BONE MARROW TR, P381
[4]   ERADICATION OF LARGE SOLID TUMORS IN MICE WITH AN IMMUNOTOXIN DIRECTED AGAINST TUMOR VASCULATURE [J].
BURROWS, FJ ;
THORPE, PE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (19) :8996-9000
[5]   SUPPRESSION OF ANTIBODY-RESPONSES TO RICIN-A CHAIN (RTA) BY MONOCLONAL ANTI-RTA ANTIBODIES [J].
BYERS, VS ;
AUSTIN, EB ;
CLEGG, JA ;
DENTON, G ;
GUNN, B ;
HOOI, D ;
HUDECZ, F ;
PRICE, MR ;
BALDWIN, RW .
JOURNAL OF CLINICAL IMMUNOLOGY, 1993, 13 (06) :406-413
[6]  
BYERS VS, 1988, IMMUNOLOGY, V65, P329
[7]   ENTRY OF LETHAL DOSES OF ABRIN, RICIN AND MODECCIN INTO THE CYTOSOL OF HELA-CELLS [J].
EIKLID, K ;
OLSNES, S ;
PIHL, A .
EXPERIMENTAL CELL RESEARCH, 1980, 126 (02) :321-326
[8]   COCKTAILS OF RICIN A-CHAIN IMMUNOTOXINS AGAINST DIFFERENT ANTIGENS ON HODGKIN AND STERNBERG-REED CELLS HAVE SUPERIOR ANTITUMOR EFFECTS AGAINST H-RS CELLS IN-VITRO AND SOLID HODGKIN TUMORS IN MICE [J].
ENGERT, A ;
GOTTSTEIN, C ;
BOHLEN, H ;
WINKLER, U ;
SCHON, G ;
MANSKE, O ;
SCHNELL, R ;
DIEHL, V ;
THORPE, P .
INTERNATIONAL JOURNAL OF CANCER, 1995, 63 (02) :304-309
[9]  
ENGERT A, 1990, CANCER RES, V50, P84
[10]   IMMUNOTOXINS CONSTRUCTED WITH ANTI-CD25 MONOCLONAL-ANTIBODIES AND DEGLYCOSYLATED RICIN A-CHAIN HAVE POTENT ANTITUMOR EFFECTS AGAINST HUMAN HODGKIN CELLS-INVITRO AND SOLID HODGKIN TUMORS IN MICE [J].
ENGERT, A ;
MARTIN, G ;
AMLOT, P ;
WIJDENES, J ;
DIEHL, V ;
THORPE, P .
INTERNATIONAL JOURNAL OF CANCER, 1991, 49 (03) :450-456